The Purification Insights Blog

QuickTip #10: Avoiding loss of activity of Ni charged IMAC columns

Have you experienced how Nickel-charged chromatography columns used for purifying His-tagged proteins lose their blue color, become a bit yellow and can’t bind your protein anymore? It can happen after only one use. No amount of washing will..

Read More

QuickTip #9: Purifying a His-tagged protein with low expression level

Do you find yourself having to deal with a very low yield of your target protein after the expression? Are you using a His-tag? Here are some ideas to help you with your purification.

Read More

QuickTip #8: Desalting oligos for therapeutic use

If you’re purifying therapeutic oligos you’ll need to clean the desalting resins afterwards in a far higher concentration of NaOH than the usual desalting resins will tolerate. This is how to solve the problem.

Read More

Process modelling for chromatography – how is it used?

Process modelling of chromatographic behavior, in an industrial setting, can be a useful tool in dealing with the complexities of purification process development, optimization and scale-up. It can be used to identify critical process parameters..

Read More

QuickTip #7: Improve purity of viruses and vaccines

Changing from purification products based on synthetic polymers to agarose-based chromatography will increase the purity of the target virus.

Read More

Enhanced Capture Process - a presentation

Just before the Christmas break, Lars, Haneskog, Bio-Works R&D Director, presented a new and proven strategy for downstream processing at the New Horizons in Biologics and Bioprocessing conference. It was met with great interest and several..

Read More

How reversing downstream bioprocess steps can make all the difference

Improving downstream bioprocess economy depends on fine-tuning an enormous range of parameters, from culture and harvesting to purification and final polishing. Success depends on the ability to troubleshoot difficulties and identify novel..

Read More

QuickTip #6: Use true buffers

A critical and fundamental factor in both analytical and preparative chromatography is the use of true buffers. In other words, mobile phases with buffering capacity. For example, in peptide purification, there are concentrated bands of various..

Read More

QuickTip #5: Filter everything

Filtering is crucial in order to protect the packed column from all solid particles in feeds or eluents. Clogging of the column will increase back-pressure and disturb the feed loading zone causing reduced resolution and it is a common problem...

Read More

Ten things you must know when producing synthetic therapeutic peptides

Peptide therapeutic agents are enjoying increasing success but they are challenging to produce and, not least, to purify. Purity requirements are, in fact, approaching those for small molecules. Synthesis generates a crude mixture containing..

Read More

QuickTip #4: yield of His-tagged proteins

Immobilized Metal Ion Affinity Chromatography (IMAC) is used for purification of His-tagged proteins. Ni-NTA based resins are the most commonly used as the Ni2+ ion is considered to have the strongest affinity to histidine-tagged proteins but..

Read More

Join the effort to make chromatography sustainable

The environmental impact of pharmaceutical R&D and production is considerable. Although the industry is rather conservative and also constrained by regulatory guidelines, there is increasing interest in the implementation of sustainable practices..

Read More

QuickTip #3: optimizing mAb purification

Designing an optimized purification process means maximizing yield and purity, and at the same time controlling costs. So, you remove a lot of bulk impurities during the first steps, and focus on high yield steps at the end, when every gram is..

Read More

Affordable and safe biosimilars for affordable healthcare

When it comes to many serious and challenging diseases, healthcare has reached a point of unsustainability, due to drug costs. For example, sustained therapy for an autoimmune disease or cancer, involving large amounts of monoclonal antibodies..

Read More

Are mAbs the ultimate targeted therapy?

Since the 1980’s, monoclonal antibodies (mAbs) have revolutionized healthcare and continue to do so. A short history of mAb approvals shows their increasing sophistication and targeting of disease mechanisms – even down to purifying them for..

Read More

QuickTip #2: choosing IEX resin

Recovery of the biological activity of your target substance is a priority, and it’s important to check for its pH and ionic strength stability values...

Read More

CHO cells in fed-batch bioreactors dominate mAb upstream processes

Choosing a mammalian cell line or other type of host is as critical a question as any other in the complex world of monoclonal antibody (mAb) manufacture. We take a look at the present status, with fed batch Chinese Hamster Ovary (CHO) cell..

Read More

QuickTip #1: cleaning IEX columns

When an IEX resin has been used for some time, impurities may build up in the column causing loss of resolution or increase in back pressure (shown on the pressure monitor or seen by gap formation on the top of the column)...

Read More

Recent (May 2019) figures for illnesses with approved monoclonal antibody therapies

As our understanding of diseases at the molecular level increases, so does the potential for monoclonal antibody (mAb) - related therapies. Platform approaches to mAb production, including purification, are a key to their successful manufacture..

Read More

Improved peptide purification promises to boost process efficiency in the race to affordable insulin in China

The global diabetes pandemic has created a massive demand for insulin, especially in China, which is expected to soon have half the world’s diabetes patients. Meeting this demand means developing extremely efficient production methods that can..

Read More

How to improve process efficiency and economy in peptide production

The purity requirements for therapeutic peptides are very stringent, but synthesis generates a crude peptide mixture containing failed sequences and chemical variants, while recombinant peptides have a considerable bioburden from the host cell...

Read More

mAb Purification – an overview of the essentials

Five of the top ten best selling drugs in 2017 were mAbs and the global mAbs market is expected to reach USD 219 billion by the end of 2023. The mAbs entering the clinic today are highly engineered and are presenting new challenges in..

Read More

The promise and the price of the new biopharmaceuticals

The healthcare sector and developers of new pharmaceuticals are facing increasing challenges, along with pressure to lower costs. At the same time pharmaceutical development is undergoing a revolution with the use of biological substances as..

Read More

Optimizing mAb purification using the next generation of protein A resin

The market for monoclonal antibodies (mAbs) is constantly growing as mAb therapies are generally considered to be both safe and effective treatments for difficult diseases like cancer and rheumatoid arthritis. The growing global demand, as well..

Read More

Some general tips on protein purification strategy

Can you generalize about something as broad as protein purification strategy? Surely it depends on the protein and the situation in general? Well, yes, of course. But there are some general aspects which might be valuable to think through before..

Read More

Optimizing mAb purification using a guard column

What are the benefits of introducing multimodal ion exchange chromatography as a guard column and could they include a significant increase in mAb purity? This article presents a study in which two protein A affinity chromatography resins were..

Read More

How to recognize an efficient protein A resin for mAbs

In short, an efficient protein A resin is one that will not only help you purify your monoclonal antibody (mAb), but also enable you to achieve good process economy. But what are the characteristics of such a resin and how can it improve your..

Read More

Three market changes that will impact the production of mAbs

In 2015, the monoclonal antibodies (mAbs) market was estimated to be USD 85,4 billion and predicted to reach approximately USD 130 billion in 2023[1]. However, new research points at a much higher number. According to Zion Market Research, the..

Read More

How pure is pure? Controlling your mAb purification process

Monoclonal antibodies, mAbs, form a well-established, technologically advanced segment of the pharmaceutical industry offering hope for large groups of patients who have difficult-to-treat cancers, rheumatoid arthritis or other serious diseases...

Read More
Copyrights © 2020 All Rights Reserved by Bio-Works.